Axon Enterprise, Inc (NASDAQ:AXON) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have received a consensus recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $762.9333.

AXON has been the topic of several research analyst reports. Needham & Company LLC lowered their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Craig Hallum reaffirmed a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. UBS Group cut their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Morgan Stanley dropped their price target on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th.

Axon Enterprise Trading Up 0.8%

Shares of NASDAQ AXON opened at $460.15 on Thursday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise has a 12 month low of $396.41 and a 12 month high of $885.91. The company has a market cap of $37.00 billion, a price-to-earnings ratio of 302.73, a P/E/G ratio of 9.75 and a beta of 1.46. The business has a fifty day simple moving average of $509.91 and a 200-day simple moving average of $595.01.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the prior year, the firm earned $2.08 EPS. The firm’s quarterly revenue was up 38.5% on a year-over-year basis. Sell-side analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, Director Jeri Williams sold 157 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total transaction of $76,930.00. Following the transaction, the director directly owned 1,159 shares of the company’s stock, valued at $567,910. This represents a 11.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Erika Nardini sold 198 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the transaction, the director directly owned 1,946 shares in the company, valued at approximately $985,804.68. This represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 23,855 shares of company stock valued at $13,299,928. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. lifted its stake in shares of Axon Enterprise by 53.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after buying an additional 4,002 shares during the last quarter. World Investment Advisors grew its stake in Axon Enterprise by 37.1% in the 4th quarter. World Investment Advisors now owns 1,035 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 280 shares during the last quarter. Pure Financial Advisors LLC raised its holdings in Axon Enterprise by 6.7% in the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 23 shares during the period. Tobam raised its holdings in Axon Enterprise by 17.3% in the 4th quarter. Tobam now owns 5,833 shares of the biotechnology company’s stock worth $3,313,000 after acquiring an additional 859 shares during the period. Finally, Clearwave Capital LLC acquired a new position in Axon Enterprise during the 4th quarter worth $325,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s AI products (DraftOne, Fusus, Drone as First Responder) are producing very large bookings and attracting both public-safety and defense interest, suggesting meaningful revenue upside and new contract opportunities. Is Axon (AXON) Quietly Shifting Its AI Defense Ambitions As Board Veteran Julie Cullivan Exits?
• Positive Sentiment: Axon reported 36% EBITDA growth and margin expansion, showing operating leverage as revenues scale — a core positive for valuation if management can sustain margins. Can Axon Sustain EBITDA Margin Momentum Amid Cost Pressures?
• Positive Sentiment: Commentary linking Axon to a proposed large U.S. defense spending push has framed Axon as a top-rated defense/security name, which could drive re-rating if defense budgets translate into larger bookings. Hegseth Says It ‘Takes Money to Kill Bad Guys’ Amid $200 Billion Spending Push. Why Axon and L3Harris Are the 2 Top-Rated Defense Stocks to Buy Now
• Positive Sentiment: Short-term price momentum: recent write-ups note Axon has outpaced the market in recent sessions, reinforcing bullish investor sentiment. Axon Enterprise (AXON) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: Short-interest reports this month show anomalous “0 shares” and 0.0 days-to-cover figures across feeds — data appears unreliable and should not be treated as a clear signal until corrected. (Multiple market-data postings)
• Negative Sentiment: Peer comparison: Teledyne (TDY) is cited as having stronger near-term defense demand and a more attractive valuation, implying Axon may face tougher relative upside if investors rotate to better-valued defense names. Axon vs. Teledyne: Which Defense & Security Stock has Greater Upside?
• Negative Sentiment: Valuation risk: broader coverage warns that high-growth, premium-valued stocks like Axon have limited margin for execution misses — rising costs noted by analysts could test expectations and amplify downside on any miss. 2 High-Flying Stocks to Keep an Eye On and 1 Facing Headwinds

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.